This site is intended for Healthcare professionals only.

FDA clears Novo Nordisk diabetes drug to treat heart diseases


FDA clears Novo Nordisk diabetes drug to treat heart diseases

Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved its diabetes drug as a treatment to reduce the risk of three major cardiovascular diseases.

This is the first time the FDA has cleared a diabetes drug to treat heart-related diseases in patients with type 2 diabetes, the company said in a statement.

The drug, Victoza, which was approved in 2010 to treat patients with type 2 diabetes, brought in 11.5 billion Danish crown ($1.84 billion) in the first six months of 2017.

Type 2 diabetes, closely linked to obesity, accounts for more than 90 percent of all diabetes cases, the company said.

Victoza’s expanded label follows a successful trial that showed the drug significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13 percent when compared to a placebo.

Heart disease is the leading cause of death in the United States, killing about 610,000 people every year, according to the Centers for Disease Control and Prevention.

Adults with type 2 diabetes are up to four times more likely to develop cardiovascular disease, the company said. ($1 = 6.2581 Danish crowns)

(Reporting by Tamara Mathias in Bengaluru; Editing by Anil D’Silva)



Source: REUTERS
0 comment(s) on FDA clears Novo Nordisk diabetes drug to treat heart diseases

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted